ITMCTR2200005612尚未招募1 期
The Trial of Effectiveness and Safety of Jingning Granules in the treatment of Attention Deficit Disorder with Hyperactivity
Dongzhimen Hospital, Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 5 至 14（—）
- 性别
- All
入选标准
- •A. Current symptoms consistent with Western medical criteria for the diagnosis of attention deficit hyperactivity disorder.
- •B. Current symptoms meet the diagnostic criteria of TCM on the evidence of ADHD in children.
- •C. Age 5 to 14 years (inclusive), gender not limited.
- •D. The subject himself/herself or his/her guardian has the will to participate in the treatment as required; if the subject is incapable of civil behavior, the written informed consent of his/her guardian shall be obtained; if the subject is a person with restricted civil behavior, the written informed consent of the subject and his/her guardian shall be obtained.
排除标准
- •Those meeting one of the following criteria were excluded.
- •A. Have childhood schizophrenia, mood disorders, developmental delays, autism, epilepsy, etc. and other psychiatric psychological disorders.
- •B. Those who were unable or unwilling to cooperate, or whose compliance, in the opinion of the investigator, was likely to be low, such as those with significant somatic and neurological abnormalities, or significant hearing or vision impairment.
- •C. Combination of other serious cardiovascular, hepatic, renal, neurological, hematopoietic, endocrine, and genetic C. Combination of other serious cardiovascular, cerebrovascular, hepatic, renal, neurological, hematopoietic, endocrine and genetic diseases or malignant tumors
- •D. Allergic individuals.
- •E. Those who have participated in other clinical trials within one month or have been treated with other drugs of the same type, such as those with related therapeutic effects or those with antagonistic effects. E. Those who have participated in other clinical trials within one month or have been treated with other drugs of the same type, such as those who have taken drugs with related therapeutic effects or drugs with antagonistic effects, making it difficult to judge the efficacy of drugs.
研究者
相似试验
进行中（未招募）
不适用
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM(Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study)+ Protocol Amendment 01 (version 1.0 dated 21-Apr-08) Site-specific - Molecular Profiling Supplement Samples For Pfizer’s Exploratory Research BiobankRevised Protocol 03 (version 5.0 dated 18-Apr-2011) incorporating Amendment 05 (version 210 dated 18-Apr-2011)EUCTR2007-004953-27-CZBristol-Myers Squibb International Corporation2,430
进行中（未招募）
1 期
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISMENSAYO PARA EVALUAR LA EFICACIA Y SEGURODAD DEL USO DE APIXABAN EN EL TRATAMIENTO AMPLIADO DE LA TROMBOSIS VENOSA PROFUNDA Y LA EMBOLIA PULMONAR Revised Protocol 01 (version 4.0 dated 21-Apr-08), incorporating Amendment 02 (version 1.0 dated 21-Apr-08)+ Protocol Amendment 01 (version 1.0 dated 21-Apr-08) Site-specific - Molecular Profiling Supplement Samples For Pfizer’s Exploratory Research BiobankProtocolo revisado 01 (versión 4.0 de fecha 21-Abril-08). Incorpora la enmienda 02 (versión 1.0 de fecha 21-Abril-08) + Enmienda del protocolo 01 (versión 1.0 de fecha 21-Abril-08)Venous Thromboembolism (VTE)Tromboembolismo venoso (TEV)MedDRA version: 9.1Level: PTClassification code 10051055Term: Deep vein thrombosisMedDRA version: 9.1Level: PTClassification code 10037377Term: Pulmonary embolismEUCTR2007-004953-27-ESBristol-Myers Squibb International Corporation2,430
进行中（未招募）
1 期
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary EmbolismEUCTR2007-004953-27-GBBristol-Myers Squibb International Corporation2,430
进行中（未招募）
不适用
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM(Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study)Revised Protocol 01 (version 4.0 dated 21-Apr-08), incorporating Amendment 02 (version 1.0 dated 21-Apr-08)+ Protocol Amendment 01 (version 1.0 dated 21-Apr-08) Site-specific - Molecular Profiling Supplement Samples For Pfizer’s Exploratory Research BiobankRevised Protocol 02 (version 4.0 dated 01-May-2009) incorporating Amendment 04 (version 2.0 dated 01-May-2009)Venous Thromboembolism (VTE)MedDRA version: 9.1Level: PTClassification code 10051055Term: Deep vein thrombosisMedDRA version: 9.1Level: PTClassification code 10037377Term: Pulmonary embolismEUCTR2007-004953-27-PTBristol-Myers Squibb International Corporation2,430
进行中（未招募）
不适用
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM(Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study)Revised Protocol 01 (version 4.0 dated 21-Apr-08), incorporating Amendment 02 (version 1.0 dated 21-Apr-08)+ Protocol Amendment 01 (version 1.0 dated 21-Apr-08) Site-specific - Molecular Profiling Supplement Samples For Pfizer’s Exploratory Research Biobank+ Revised Protocol 02 (version 4.0 dated 01-May-2009) incorporating Protocol Amendment 04 (version 2.0 dated 01-May-2009)EUCTR2007-004953-27-DKBristol-Myers Squibb International Corporation2,430